Kinetics of anthracycline efflux from multidrug resistance protein- expressing cancer cells compared with P-glycoprotein-expressing cancer cells

Molecular Pharmacology

Volumn 53, Issue 1, 1998, Pages 141-147

  Marbeuf Gueye, C ^a   Broxterman, H J ^b   Dubru, F ^a   Priebe, W ^c   Garnier Suillerot, A ^a  

^a UNIVERSITÉ PARIS 13   (France)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2' BROMO 4' EPIDAUNORUBICIN; 3' DEAMINO 3' HYDROXYDAUNORUBICIN; 3' DEAMINO 3' HYDROXYDOXORUBICIN; ANTHRACYCLINE ANTIBIOTIC AGENT; CARRIER PROTEIN; GLUTATHIONE; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN; PIRARUBICIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CELL STRAIN K 562; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BINDING SITE; DRUG TRANSPORT; ENZYME SPECIFICITY; HUMAN; HUMAN CELL; LIPOPHILICITY; MICHAELIS CONSTANT; MULTIDRUG RESISTANCE; PKA; PRIORITY JOURNAL;

EID: 0031891628     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.53.1.141     Document Type: Article

References (41)

1. Borrel M-N, Fiallo M, Veress I. and Garnier-Suillerot A (1995) The effect of crown ethers, tetraalkylammonium salts, and polyoxyethylene amphiphiles on pirarubicin incorporation in K562 resistant cells. Biochem Pharmacol 50:2069-2076.
2. Borrel M-N, Pereira E, Fiallo M, and Garnier-Suillerot A (1994a) Mobile ionophores are a novel class of P-glycoprotein inhibitors. The effects of ionophores on 4′-O-tetrahydropvranyl-adriamycin incorporation in K562 drug-resistant cells. Eur J Biochem 223:125-133.
3. Borrel M-N, Fiallo M, Priebe W and Garnier-Suillerot A (1994b) P-glycoprotein mediated efflux of hydroxyrubicin, a neutral anthracycline derivative, in resistant K562 cells. FEBS Lett 356:287-290.
4. Bradley G, Juranka PF and Ling V (1988) Mechanism of multidrug resistance. Biochim Biophys Acta 948:87-128.
5. Broxterman HJ and Pinedo HM (1991) Energy metabolism in multidrug resistant tumor cells: a review. J Cell Pharmacol 2:239-247.
6. Broxterman HJ, Jansen G, Linn SC, and Lankelma J (1995a) The impact of transport-associated resistance in anticancer chemotherapy, in Drug Transport in Antimicrobial and Anticancer Chemotherapy (NH Georgopapadakou, ed). Dekker, New York, 21-62.
7. Broxterman HJ, Giaccone G, and Lankelma J (1995b) Multidrug resistance proteins and other drug transport-related resistance to natural product agents. Curr Opin Oncol 7:532-540.
8. Broxterman HJ, Heijn M, and Lankelma J (1996) How does the MRP/GS-X pump export doxorubicin? J Natl Cancer Inst 88:466-467.
9. Broxterman HJ, Schuurhuis GJ, Lankelma J, Oberink JW, Eekman CA, Claessen AME, Hoekman K, Poot M, and Pinedo HM (1997) Highly sensitive and specific detection of P-glycoprotein function for hematological and solid tumor cells using a novel nucleic acid stain. Br J Cancer, in press.
10. Cole SPC, Sparks KE, Fraser K, Loe DW, Grant CE, Wilson GM, and Deeley RG (1994) Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 54:5902-5910.
11. Cornwell MM, Tsuruo T, Gottesman MM, and Pastan I (1987) ATP-binding properties of P-glycoprotein from multidrug-resistant KB cells. FASEB J 1:51-54.
12. Davey RA, Longhurst TJ, Davey MW, Belov L, Harvie RM, Hancox D, and Wheeler H (1995) Drug resistance mechanisms and MRP expression in response to epirubicin treatment in a human leukaemia cell line. Leukemia Res 19:275-282.
13. Frézard F and Garnier-Suillerot A (1991a) Determination of the osmotic active drug concentration in the cytoplasm of anthracycline-resistant and-sensitive K562 cells. Biochim Biophys Acta 1091:29-35.
14. Frézard F and Garnier-Suillerot A (1991b) Comparison of the membrane transport of anthracycline derivatives in drug-resistant and drug-sensitive K562 cells. Eur J Biochem 196:483-491.
15. Feller N, Broxterman HJ, Währer DCR, and Pinedo HM (1995) ATP-dependent efflux of calcein by the multidrug resistance protein (MRP): no inhibition by intracellular glutathione depletion. FEBS Lett 308:385-388.
16. Garnier-Suillerot A (1995) Impaired accumulation of drug in multidrug resistant cells. What are the respective contributions of the kinetics of uptake and of P-glycoprotein-mediated efflux of drug? Curr Pharmaceut Design 1:69-82.
17. 4 receptor antagonist MK571 specifically modulates MRP associated multidrug resistance. Biochem Biophys Res Commun 208:345-352.
18. Heijn M, Hooijberg JH, Scheffer GL, Szabó G, Westerhoff HV, and Lankelma J (1997) Anthracyclines modulate multidrug resistance protein (MRP) mediated organic anion transport. Biochim Biophys Acta 1326:12-22.
19. Hill T (1985) Cooperative Theory in Biochemistry. Springer-Verlag, Berlin, 63-67.
20. Hooijberg JH, Heijn M, Fles DLA, Lankelma J, Pinedo HM and Broxterman HJ (1997). Substrate interaction and ATPase activity of multidrug resistance protein (MRP). Proc Am Assoc Cancer Res 38:392.
21. Hughes AL (1994) Evolution of the ATP-binding cassette transmembrane transporters of vertebrates. Mol Biol Evol 11:899-910.
22. Ishikawa T, Akimaru K, Tien Kuo M, Priebe W, and Suzuki M (1995) How does the MRP/GS-X pump export doxorubicin? J Natl Cancer Inst 87:1639-1640
23. Kimmich, G, Randles J, and Brand J (1975) Assay of picomole amounts of ATP, ADP and AMP using the luciferase enzyme system. Anal Biochem 69:187-192.
24. 4 and structurally related conjugates. J Biol Chem 269:27807-27810.
25. Loe DW, Deeley RG, and Cole SPC (1996a) Biology of the multidrug resistance-associated protein. Eur J Cancer 32A:945-957.
26. 4 and chemotherapeutic agents in membrane vesicles. J Biol Chem 271:9675-9682.
27. Paul S, Breuninger LM, and Kruh GD (1996) ATP-dependent transport of lipophilic cytotoxic drugs by membrane vesicles prepared from MRP-overexpressing HL60/ADR cells. Biochemistry 35:14003-14011.
28. Mankhetkorn S, Dubru F, Hesschenbrouck J, Fiallo M, and Garnier-Suillerot A (1996) Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin, daunorubicin,. 8-(S)-fluoroidarubicin, and idarubicin in multidrug-resistant K562 cells. Mol Pharmacol 49:532-539;
29. Pearce HL, Safa AR, Winter NJ, Cirtain MC and Beck WT (1989) Essential features of the P-glycoprotein pharmacophore as defined by a series of reserpine analogs that modulate multidrug resistance. Proc Natl Acad Sci (USA) 86:5128-5132.
30. Pereira E, Borrel M-N, Fiallo M and Garnier-Suillerot A (1994) Non-competitive inhibition of P-glycoprotein-associated efflux of THP-adriamycin by verapamil in living K562 leukemia cells. Biochem Biophys Acta 1225:209-216.
31. Priebe W, Van NT, Burke TG and Perez-Soler R (1993) Removal of the basic center from doxorubicin partially overcomes multidrug resistance and decreases cardiotoxicity. Anti-cancer Drug Des 4:37-48.
32. Priebe W (1995) Mechanism of action-governed design of anthracycline antibiotics: a "turn-off/turn-on" approach. Curr Pharmaceut Des 1:51-68.
33. Rekker RF (1977) The hydrophobic fragmental. Its derivation and applications. A means of characterizing membrane systems, in Pharmacochemistry Library, vol 1 (Nauta W and Rekker R, eds) pp 39-103, Elsevier, Amsterdam.
34. Shen H, Paul S, Breuninger LM, Ciaccio PJ, Laing NM, Helt M, Tew KD, and Kruh GD (1996) Cellular and in vitro transport of glutathione conjugates by MRP. Biochemistry 35:5719-5725.
35. Spoelstra E, Westerhoff H, Dekker H, and Lankelma J (1992) Kinetics of daunorubicin transport by P-glycoprotein of Intact cells. Eur J Biochem 207:567-579.
36. Twentyman PR, Rhodes T, and Rayner S (1994) A comparison of rhodamine 123 accumulation and efflux in cells with p-glycoprotein-mediated and MRP-associated multidrug resistance phenotypes. Eur J Cancer 30A:1360-1369.
37. Versantvoort CHM, Broxterman HJ, Feller N, Dekker H, Kuiper CHM, and Lankelma J (1992) Probing daunorubicin accumulation defects in non-P-glycoprotein expressing multidrug-resistant cell lines using digitonin. Int J Cancer 50:906-911.
38. Versantvoort CHM, Broxterman HJ, Lankelma J. Feller N, and Pinedo HM (1994) Competitive inhibition by genistein and ATP dependence of daunorubicin transport in intact MRP overexpressing human small cell lung cancer cells. Biochem Pharmacol 48:1129-1136.
39. Versantvoort CHM, Broxterman HJ, Bagrij T, Scheper R,J and Twentyman P R (1995). Regulation by glutathione of drug transport in multidrug resistant human tumour cell lines overexpressing MRP. Br J Cancer 72:82-89.
40. Zaman GJR, Flens MJ, van Leusden MR, de Haas M, Mülder HS, Lankelma J, Pinedo HM, Scheper RJ, Baas F, Broxterman HJ, and Borst P (1994) The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc Natl Acad Sci USA 91:8822-8826.
41. Zijlstra JG, de Vries EGE, and Mulder NH (1987) Multifactorial drug resistance in an adriamycin-resiatant human small cell lung carcinoma cell line. Cancer Res 47:1780-1784.